Urology
Volume 61, Issue 1 , Pages 10-12 , January 2003

Informed consent for prostate-specific antigen-based screening

  • Otis W Brawley

      Affiliations

    • Georgia Cancer Center, Winship Cancer Institute, and Departments of Medicine, Oncology, and Epidemiology, Emory University School of Medicine, Atlanta, Georgia, USA
    • Corresponding Author InformationReprint requests: Otis W. Brawley, M.D., Winship Cancer Institute, Building B, Suite 4100, 1365-B Clifton Road, Northeast, Atlanta, GA 30322, USA

Received 26 August 2002 ,Accepted 18 October 2002.

References 

  1. Sweat GT: Prostate cancer screening recommendations from organized medicine, in Thomson IM, Resnick MI, and Klein EA (Eds): Prostate Cancer Screening. Humana Press, 2001, pp 209–222
  2. Smith RA, von Eschenbach AC, Wender R, et al.  American Cancer Society guidelines for the early detection of cancer (update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also, update 2001–testing for early lung cancer detection). CA Cancer J Clin. 2001;51:38–75
  3. American Urological Association (AUA): Prostate-specific antigen (PSA) best practice policy. Oncology (Huntingt) 14:267–268, 280, 2001
  4. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al.  Lung cancer mortality in the Mayo Lung Project (impact of extended follow-up). J Natl Cancer Inst. 2000;92:1308–1316
  5. Woods WG, Gao RN, Shuster JJ, et al.  Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041–1046
  6. Woods WG. Substitute “prostate cancer” for “neuroblastoma”?. J Clin Oncol. 2002;20:1154–1155
  7. Brawley OW. Prostate carcinoma incidence and patient mortality (the effects of screening and early detection). Cancer. 1997;80:1857–1863
  8. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998;90:1230–1231
  9. McGregor M, Hanley JA, Boivin JF, et al.  Screening for prostate cancer (estimating the magnitude of overdetection). Can Med Assoc J. 1998;159:1368–1372
  10. Zappa M, Ciatto S, Bonardi R, et al.  Overdiagnosis of prostate carcinoma by screening (an estimate based on the results of the Florence Screening Pilot Study). Ann Oncol. 1998;9:1297–1300
  11. Lu-Yao GL, Potosky AL, Albertsen PC, et al.  Follow-up prostate cancer treatments after radical prostatectomy (a population-based study). J Natl Cancer Inst. 1996;88:166–173
  12. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–910
  13. Crawford ED, Leewansangtong S, Goktas S, et al.  Efficiency of prostate-specific antigen and digital rectal examination in screening using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate. 1999;38:296–302
  14. Bubolz T, Wasson JH, Lu-Yao G, et al.  Treatments for prostate cancer in older men: 1984–1997. Urology. 2001;58:977–982
  15. Lu-Yao GL, McLerran D, Wasson J, et al.  An assessment of radical prostatectomy (time trends, geographic variation, and outcomes). JAMA. 1993;269:2633–2636
  16. Fowler FJ, Barry MJ, Lu-Yao G, et al.  Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience: 1988–1990 (updated June 1993). Urology. 1993;42:622–629
  17. Fowler FJ, Barry MJ, Lu-Yao G, et al.  Effect of radical prostatectomy for prostate cancer on patient quality of life (results from a Medicare survey). Urology. 1995;45:1007–1013
  18. Fowler FJ, Barry MJ, Lu-Yao G, et al.  Outcomes of external-beam radiation therapy for prostate cancer (a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas). J Clin Oncol. 1996;14:2258–2265

PII: S0090-4295(02)02323-3

Urology
Volume 61, Issue 1 , Pages 10-12 , January 2003

Article Tools